|
IL279174D0
|
|
Methods of treating subjects having diabetes with chronic kidney disease
|
|
WO2021037702A1
|
|
Pharmaceutical combination of a specific thienopyridone derivative with an fxr agonist for the treatment of liver diseases
|
|
WO2020099678A1
|
|
Monohydrate potassium salt of a thienopyridone derivative and its preparation process
|
|
KR20210003786A
|
|
Film-coated tablet containing a triazine derivative for use in the treatment of diabetes
|
|
WO2019069230A1
|
|
Methods of treating heart failure with preserved ejection fraction
|
|
EP2679591A1
|
|
Thienopyridone derivatives useful as activators of AMPK
|
|
AU2011334992A1
|
|
Separation of triazine derivatives enantiomers using tartaric acid
|
|
EP2579879A1
|
|
Triazine derivatives for delaying the onset of type 1 diabetes
|
|
TW201206443A
|
|
Treatment of type 2 diabetes
|
|
TW201144318A
|
|
Activators of ampk and therapeutic uses thereof
|
|
EP2453898A1
|
|
Amino derivatives of dihydro-1,3,5-triazine for use in the treatment of ischemia and/or reperfusion related diseases
|
|
WO2011006983A1
|
|
Amino derivatives of dihydro-1,3,5-triazine for treating oxidative stress
|
|
WO2010109015A1
|
|
Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization
|
|
CA2745854A1
|
|
Tetrahydrotriazine compounds for treating diseases associated with ampk activity
|
